Kingview Biomedical

Kingview Biomedical is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the development of innovative adeno-associated virus (AAV) gene therapies. The company focuses on high-unmet-need areas, specifically metabolic disorders, rare diseases, and ophthalmic conditions. Kingview possesses a vertically integrated model that combines a proprietary AAV vector discovery platform with internal large-scale GMP manufacturing capabilities. Its lead asset, KV-001, is a gene therapy candidate targeting transthyretin amyloidosis (ATTR), currently in clinical development. Beyond its lead program, the company is advancing a robust pipeline of gene replacement therapies for conditions like Hemophilia B and Fabry disease. Kingview aims to provide long-lasting, curative treatments for patients through its sophisticated viral vector engineering and production systems.